Literature DB >> 3220177

The 30-minute aminopyrine breath test: optimization of sampling times after intravenous administration of 14C-aminopyrine.

T Miotti1, J Bircher, R Preisig.   

Abstract

In a retrospective analysis of 78 well-defined patients, the procedure of the aminopyrine breath test was evaluated. After intravenous administration of 14C-aminopyrine (1.5 microCi, 1 mg) 14CO2 was sampled at 15-min intervals for 1 h. Samples taken at 15, 30, 45 and 60 min were similarly able to distinguish between patients with mild liver disease and patients with enzyme induction. The results of the aminopyrine breath test at each sampling time were highly correlated with the galactose elimination capacity and the fractional clearance of indocyanine green. It is concluded that sampling at 30 min represents a satisfactory compromise between practicality and accuracy of the test.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3220177     DOI: 10.1159/000199632

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  12 in total

1.  Influence of low-dose oral contraceptives, alcohol, and grapefruit on.

Authors:  H Van Vlierberghe; F Van Durme; H Verdievel; M Dhont; M de Vos; A Elewaut
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

2.  Lack of interference by sorbitol with aminopyrine breath test.

Authors:  V C Ramin; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Reliability of aminopyrine breath test using a single breath collection.

Authors:  Y Horsmans; A P Geubel; S Pauwels
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

4.  Preliminary studies of a canine 13C-aminopyrine demethylation blood test.

Authors:  E M Moeller; J M Steiner; D A Williams; P D Klein
Journal:  Can J Vet Res       Date:  2001-01       Impact factor: 1.310

5.  Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis.

Authors:  J Cotting; M J Lentze; J Reichen
Journal:  Gut       Date:  1990-08       Impact factor: 23.059

6.  Parameters of microsomal and cytosolic liver function but not of liver perfusion predict portal vein velocity in noncirrhotic patients with chronic hepatitis C.

Authors:  C Herold; P Berg; D Kupfal; D Becker; D Schuppan; E G Hahn; H T Schneider
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

7.  No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Authors:  Karin Wåhlander; Maria Eriksson-Lepkowska; Lars Frison; Gunnar Fager; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Use of a 13C-aminopyrine blood test: first clinical impressions.

Authors:  Deirdre Chiaramonte; Jörg M Steiner; John D Broussard; Keith Baer; Sheila Gumminger; Erik M Moeller; David A Williams; Renée Shumway
Journal:  Can J Vet Res       Date:  2003-07       Impact factor: 1.310

9.  Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis?

Authors:  Christoph Herold; Sabine Regn; Marion Ganslmayer; Matthias Ocker; Eckhart G Hahn; Detlef Schuppan
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

10.  Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations.

Authors:  D Ullrich; D Compagnone; B Münch; A Brandes; H Hille; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.